J. Goldman & CO LP Axsome Therapeutics, Inc. Call Options Transaction History

J. Goldman & CO LP

6 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q4 2023 Feb 14, 2024	BUY	$57.42 - $83.61 $1.29 Million - $1.88 Million	22,500 New	22,500 $1.79 Million
Q1 2020 May 15, 2020	SELL	$41.2 - $101.31 $1.24 Million - $3.04 Million	-30,000 Closed	0 $0
Q4 2019 Feb 14, 2020	SELL	$16.71 - $106.24 $501,300 - $3.19 Million	-30,000 Reduced 50.0%	30,000 $3.1 Million
Q3 2019 Nov 14, 2019	SELL	$20.24 - $29.16 $101,199 - $145,800	-5,000 Reduced 7.69%	60,000 $1.21 Million
Q2 2019 Aug 14, 2019	SELL	$13.46 - $25.75 $874,900 - $1.67 Million	-65,000 Reduced 50.0%	65,000 $1.67 Million
Q1 2019 May 14, 2019	BUY	$2.63 - $16.34 $341,900 - $2.12 Million	130,000 New	130,000 $1.85 Million

325

37.7M

912K

855K

Ticker AXSM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 42,878,000
Market Cap $3.89B
Description
Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's product pipeline includes AXS-05, a therapeutic for the treatment of major depressive disorder and resistant depression disorders; and that is in the Phase III clinic...

Get notified when there are updates to the investment portfolio of J. Goldman & CO LP, based on Form 13F filings with the SEC.

Stay updated on J. Goldman & CO LP with notifications on news.